Phase I trial of SAGE 689
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2015
At a glance
- Drugs SAGE 689 (Primary)
- Indications Status epilepticus
- Focus Adverse reactions
- Sponsors Sage Therapeutics
- 15 Dec 2015 According to a Sage Therapeutics media release, this trial is expected to be initiated in the second half of 2016.
- 05 Nov 2015 According to a media release, SAGE Therapeutics is delaying the initiation of phase I trial of SAGE-689 to respond to requests from the U.S. FDA for additional non-clinical study data unrelated to toxicology.
- 09 Mar 2015 New trial record